<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00420966</url>
  </required_header>
  <id_info>
    <org_study_id>456-2005</org_study_id>
    <nct_id>NCT00420966</nct_id>
  </id_info>
  <brief_title>Utilization and Compliance of Respiratory Syncytial Virus Monoclonal Antibody Therapy</brief_title>
  <official_title>Phase IV Study of Respiratory Syncytial Virus Monoclonal Antibody Therapy in High-risk Infants and Toddlers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sunnybrook Health Sciences Centre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sunnybrook Health Sciences Centre</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the utilization patterns and compliance rates of
      palivizumab, which is a monoclonal antibody therapy used to prevent respiratory syncytial
      virus infection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Respiratory syncytial virus (RSV) is the most important viral respiratory pathogen in
      children. Infection due to RSV represents a large public health burden; in Canada, it
      accounts for 5,800 hospitalizations annually. The peak incidence of RSV disease occurs
      between 2-6 months of age with half of all infants infected in the first year of life.
      Palivizumab has been approved for the prevention of serious lower respiratory tract disease
      caused by RSV in pediatric patients at high-risk of RSV disease. These children include those
      born premature, those with bronchopulmonary dysplasia (BPD), and those with hemodynamically
      significant congenital heart disease (CHD).

      With the recent approval of palivizumab in Canada, access to this medication has increased.
      However, there are limited data on utilization, compliance, and health outcomes, particularly
      the frequency and severity of RSV infections. The primary objective of this study is to
      provide insight into the current management (utilization, compliance) of children at
      high-risk of RSV infection with palivizumab prophylaxis in the tertiary care centers and
      community settings through the development of a Canadian Registry Database.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2005</start_date>
  <completion_date type="Actual">June 26, 2017</completion_date>
  <primary_completion_date type="Actual">June 26, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Determine palivizumab outcome measures</measure>
    <time_frame>Per respiratory syncytial virus season</time_frame>
    <description>The objectives of this study are:
To determine palivizumab usage patterns, annually
To understand palivizumab infant demographics, including: potential neonatal, familial and environmental risk factors
To determine reasons for hospitalization, respiratory syncytial virus hospitalization rates, length of stay, morbidity and mortality
To determine intensive care unit admissions, length of stay, use of respiratory support (e.g., mechanical ventilation, CPAP) and complication rates
To determine compliance rates
To collect safety data</description>
  </primary_outcome>
  <enrollment type="Actual">25003</enrollment>
  <condition>Lower Respiratory Tract Infection</condition>
  <condition>Respiratory Syncytial Virus Infections</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Children who have received at least one dose of palivizumab.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All children who receive at least one dose of palivizumab

        Exclusion Criteria:

          -  The child's parent or legal guardian could not communicate in either English or French

          -  The child had received palivizumab as part of a clinical trial during the study period
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ian Mitchell, MB, FRCPC</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Calgary</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Krista L Lanctôt, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Sunnybrook Health Sciences Centre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bosco Paes, MD, FRCPC</last_name>
    <role>Study Director</role>
    <affiliation>McMaster University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Alberta Children's Hospital</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T3B 6A8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McMaster Children's Hospital</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 3Z5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <results_reference>
    <citation>Mitchell I, Paes BA, Li A, Lanctôt KL; CARESS investigators. CARESS: the Canadian registry of palivizumab. Pediatr Infect Dis J. 2011 Aug;30(8):651-5. doi: 10.1097/INF.0b013e31821146f7.</citation>
    <PMID>21343842</PMID>
  </results_reference>
  <results_reference>
    <citation>Paes B, Mitchell I, Li A, Lanctôt KL; CARESS Investigators. A comparative study of respiratory syncytial virus (RSV) prophylaxis in premature infants within the Canadian Registry of Palivizumab (CARESS). Eur J Clin Microbiol Infect Dis. 2012 Oct;31(10):2703-11. Epub 2012 May 1.</citation>
    <PMID>22546928</PMID>
  </results_reference>
  <results_reference>
    <citation>Paes B, Mitchell I, Yi H, Li A, Lanctôt KL; CARESS Investigators. Hospitalization for respiratory syncytial virus illness in Down syndrome following prophylaxis with palivizumab. Pediatr Infect Dis J. 2014 Feb;33(2):e29-33. doi: 10.1097/INF.0000000000000019.</citation>
    <PMID>23989104</PMID>
  </results_reference>
  <results_reference>
    <citation>Yi H, Lanctôt KL, Bont L, Bloemers BL, Weijerman M, Broers C, Li A, Kiss A, Mitchell I, Paes B; CARESS investigators. Respiratory syncytial virus prophylaxis in Down syndrome: a prospective cohort study. Pediatrics. 2014 Jun;133(6):1031-7. doi: 10.1542/peds.2013-3916. Epub 2014 May 5.</citation>
    <PMID>24799541</PMID>
  </results_reference>
  <results_reference>
    <citation>Chen JJ, Chan P, Paes B, Mitchell I, Li A, Lanctôt KL; CARESS investigators. Serious Adverse Events in the Canadian Registry of Children Receiving Palivizumab (CARESS) for Respiratory Syncytial Virus Prevention. PLoS One. 2015 Aug 3;10(8):e0134711. doi: 10.1371/journal.pone.0134711. eCollection 2015.</citation>
    <PMID>26237402</PMID>
  </results_reference>
  <results_reference>
    <citation>Chan P, Li A, Paes B, Abraha H, Mitchell I, Lanctôt KL; CARESS investigators. Adherence to Palivizumab for Respiratory Syncytial Virus Prevention in the Canadian Registry of Palivizumab. Pediatr Infect Dis J. 2015 Dec;34(12):e290-7. doi: 10.1097/INF.0000000000000922.</citation>
    <PMID>26780032</PMID>
  </results_reference>
  <results_reference>
    <citation>Hui C, Paes B, Papenburg J, Mitchell I, Li A, Lanctôt KL; CARESS Investigators. Palivizumab Adherence and Outcomes in Canadian Aboriginal Children. Pediatr Infect Dis J. 2016 Nov;35(11):1187-1193.</citation>
    <PMID>27331856</PMID>
  </results_reference>
  <results_reference>
    <citation>Paes B, Mitchell I, Li A, Harimoto T, Lanctôt KL. Respiratory-related hospitalizations following prophylaxis in the Canadian registry for palivizumab (2005-2012) compared to other international registries. Clin Dev Immunol. 2013;2013:917068. doi: 10.1155/2013/917068. Epub 2013 Jun 19.</citation>
    <PMID>23861694</PMID>
  </results_reference>
  <results_reference>
    <citation>Paes B, Mitchell I, Li A, Lanctôt KL. Respiratory hospitalizations and respiratory syncytial virus prophylaxis in special populations. Eur J Pediatr. 2012 May;171(5):833-41. doi: 10.1007/s00431-011-1654-8. Epub 2011 Dec 28. Erratum in: Eur J Pediatr. 2012 Sep;171(9):1419.</citation>
    <PMID>22203430</PMID>
  </results_reference>
  <results_reference>
    <citation>Manzoni P, Paes B, Lanctôt KL, Dall'Agnola A, Mitchell I, Calabrese S, Maule M, Girardi E, Harimoto T, Li A. Outcomes of Infants Receiving Palivizumab Prophylaxis for Respiratory Syncytial Virus in Canada and Italy: An International, Prospective Cohort Study. Pediatr Infect Dis J. 2017 Jan;36(1):2-8.</citation>
    <PMID>27649365</PMID>
  </results_reference>
  <results_reference>
    <citation>Wang DY, Li A, Paes B, Mitchell I, Lanctôt KL; CARESS Investigators. First versus second year respiratory syncytial virus prophylaxis in chronic lung disease (2005-2015). Eur J Pediatr. 2017 Mar;176(3):413-422. doi: 10.1007/s00431-017-2849-4. Epub 2017 Jan 20.</citation>
    <PMID>28105526</PMID>
  </results_reference>
  <results_reference>
    <citation>Li A, Wang DY, Lanctôt KL, Mitchell I, Paes BA; CARESS Investigators. Comparing First- and Second-year Palivizumab Prophylaxis in Patients With Hemodynamically Significant Congenital Heart Disease in the CARESS Database (2005-2015). Pediatr Infect Dis J. 2017 May;36(5):445-450. doi: 10.1097/INF.0000000000001357.</citation>
    <PMID>28403044</PMID>
  </results_reference>
  <results_reference>
    <citation>Bjornson C, Chan P, Li A, Paes B, Lanctôt KL, Mitchell I. Palivizumab prophylaxis for respiratory syncytial virus in infants with cystic fibrosis: is there a need? Eur J Clin Microbiol Infect Dis. 2018 Jun;37(6):1113-1118. doi: 10.1007/s10096-018-3225-7. Epub 2018 Mar 19.</citation>
    <PMID>29557081</PMID>
  </results_reference>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 10, 2007</study_first_submitted>
  <study_first_submitted_qc>January 10, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 11, 2007</study_first_posted>
  <last_update_submitted>April 13, 2018</last_update_submitted>
  <last_update_submitted_qc>April 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>lower respiratory tract infection</keyword>
  <keyword>respiratory syncytial virus infections</keyword>
  <keyword>palivizumab</keyword>
  <keyword>outcomes</keyword>
  <keyword>utilization</keyword>
  <keyword>compliance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
    <mesh_term>Respiratory Tract Infections</mesh_term>
    <mesh_term>Respiratory Syncytial Virus Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

